Barr antitrust suit moves forward
WASHINGTON A group of antitrust cases against Barr Pharmaceuticals and Warner Chilcott filed by three store chains will continue, a federal district court judge has ruled.
Walgreens, CVS and Midwestern big-box chain Meijer filed the suit against the generic drug maker in the United States District Court for the District of Columbia, alleging that Barr and drug maker Warner Chilcott violated antitrust laws in 2004 by agreeing to delay introduction of a generic version of Warner Chilcott’s hormone contraceptive Ovcon (ethinyl estradiol/norethindrone).
Following a settlement between the chains and Warner Chilcott, however, Barr is now the sole defendant.
Under the agreement, Barr agreed with Warner Chilcott that for a five-year period, it would not sell the generic Ovcon and would supply Warner Chilcott with the drug. Barr said the agreement favored consumers and competition.
The court ruled that the agreement did not violate antitrust laws, but it could not resolve the definition of the market for the drug on summary judgment. A status hearing will take place Sept. 17.
Teva’s Azilect slows Parkinson’s disease in trials
WASHINGTON Results from a Phase III clinical trial have shown that Teva Pharmaceutical’s Azilect 1-mg tablets can slow the progression of the disease, the drug maker announced.
Researchers gave 1,176 Parkinson’s disease patients daily 1- to 2-mg doses of Azilect for 18 months or a placebo for the first nine months and the drug for the second nine months.
Patients who took the 1-mg dose of Azilect showed significant improvement compared with patients in the placebo group.
The Food and Drug Administration approved Azilect in May 2006 as a monotherapy for early-stage ParkinsonOs disease and as an adjunct therapy to levodopa in moderate-to-advanced stages of the disease.
The drug, known generically as rasagiline mesylate, is available in 30 countries. Danish drug maker Lundbeck markets it in Europe, and both companies plan to co-promote it in the United Kingdom, Germany and France.
Taro to ask for extension on Sun Pharmaceuticals’ offer
TEL AVIV,, Israel Taro Pharmaceutical Industries has said it will appeal to Israel’s Supreme Court to contest a ruling in the Tel Aviv District Court regarding India-based Sun Pharmaceuticals’ offer to acquire the Israeli generic drug maker.
The District Court judge had called Taro’s demand for a tender offer from Sun disingenuous, considering Taro’s acceptance of the offer a year ago.
Taro plans to ask the Supreme Court to extend the deadline for Sun’s offer, which was Tuesday at 5 p.m.